CollPlant: Ami Sagy's stake falls to about 5.7%

Issuer share issuances explain the lower reported percentage; Ami Sagy says he made no acquisitions or dispositions since his prior amendment.

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd. reports that Ami Sagy, manager of the Sagy Group, beneficially owns 163,709 ordinary shares, or approximately 5.7% of the class. The reported percentage decreased because CollPlant issued ordinary shares since Amendment No. 4, filed November 28, 2025; Sagy says he did not acquire or dispose of shares since then and reported no transactions during the 60 days preceding this amendment. He has sole voting and dispositive power over the reported shares. The percentage uses 2,866,715 ordinary shares outstanding as of September 30, 2026, reflecting the issuer's 1-for-10 reverse share split effective September 4, 2026. Sagy states he is eligible to begin reporting on Schedule 13G under Rule 13d-1(c).

Key Figures

Beneficially owned ordinary shares: 163,709 shares Beneficial ownership: Approximately 5.7% Ordinary shares outstanding: 2,866,715 shares +1 more

4 metrics

Beneficially owned ordinary shares 163,709 shares Ami Sagy's reported holdings

Beneficial ownership Approximately 5.7% Based on 2,866,715 ordinary shares outstanding as of September 30, 2026

Ordinary shares outstanding 2,866,715 shares As of September 30, 2026

Reverse share split 1-for-10 Effective September 4, 2026

Key Terms

beneficially owned, sole voting power, sole dispositive power, Rule 13d-1(c)

4 terms

beneficially owned financial

"aggregate amount beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole Voting Power"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole Dispositive Power"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Rule 13d-1(c) regulatory

"eligible to begin reporting his beneficial ownership on Schedule 13G under Rule 13d-1(c)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CLGN shares does Ami Sagy beneficially own?

Ami Sagy reported beneficial ownership of 163,709 ordinary shares, with sole voting and sole dispositive power over that amount.

Why did Ami Sagy's reported CLGN ownership percentage decrease?

He attributed the decrease to CollPlant's issuances of ordinary shares since Amendment No. 4, filed November 28, 2025. He stated that he did not acquire or dispose of shares since that amendment.

Did Ami Sagy trade CLGN shares recently?

He reported no transactions in ordinary shares during the 60 days preceding this amendment, and no acquisitions or dispositions since Amendment No. 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/08/2026 - 10:54 AM Accepted by SEC EDGAR 10/08/2026 - 10:54 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)

CollPlant Biotechnologies Ltd.

(Name of Issuer)

Ordinary Shares, no par value per share (including Ordinary Shares represented by American Depositary Shares at a 1-to-1 ratio)

(Title of Class of Securities)

M2R51X124

(CUSIP Number)

Jonathan M. Nathan, Adv.
Meitar Law Offices, 1 Ariel Sharon Street
Givatayim, L3, 5320048
972-3-610-3100

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/30/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): M2R51X124

1

Name of reporting person

Ami Sagy

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

ISRAEL

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 163,709.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 163,709.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

163,709.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.7 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

Row 13: The percent of class set forth in row 13 is based on 2,866,715 ordinary shares outstanding as of September 30, 2026, which information was provided by the Issuer in response to the Reporting Person's request and which reflects the Issuer's 1-for-10 reverse share split that was effective on September 4, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, no par value per share (including Ordinary Shares represented by American Depositary Shares at a 1-to-1 ratio)
(b)	Name of Issuer: CollPlant Biotechnologies Ltd.
(c)	Address of Issuer's Principal Executive Offices: 4 Oppenheimer, Weizmann, Science Park, Rehovot, ISRAEL , 7670104.
Item 2.	Identity and Background
(a)	Ami Sagy
(b)	66 Pinkas Street, Tel Aviv, Israel 62157
(c)	The Reporting Person serves as manager of the Sagy Group, which manages bank charges and reduces financial costs for medium to large organizations and institutions. The principal address of the offices at which the Reporting Person is employed is 84 Ben-Tzvi Road, Tel Aviv 68104, Israel.
(d)	During the last five years, the Reporting Person has not been convicted in a criminal proceeding.
(e)	During the last five years, the Reporting Person was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	The Reporting Person is a citizen of Israel.
Item 3.	Source and Amount of Funds or Other Consideration
	No funds were used in connection with any transactions reported in this Amendment No. 5, which is being filed to report a decrease in the Reporting Person's percentage beneficial ownership resulting from issuances of Ordinary Shares by the Issuer.
Item 4.	Purpose of Transaction
	The Reporting Person is filing this Amendment No. 5 to Schedule 13D ("Amendment No. 5") to report that, as a result of issuances of Ordinary Shares by the Issuer since the filing of Amendment No. 4 to Schedule 13D on November 28, 2025, his beneficial ownership percentage has decreased to approximately 5.7% of the outstanding Ordinary Shares. The Reporting Person has not acquired or disposed of any Ordinary Shares since the filing of Amendment No. 4. The Reporting Person holds the Ordinary Shares reported herein for investment purposes only, and in the ordinary course, and not with the purpose or effect of changing or influencing control of the Issuer, and is therefore eligible to begin reporting his beneficial ownership on Schedule 13G under Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person may, from time to time, based on various factors, acquire additional Ordinary Shares of the Issuer or sell Ordinary Shares, on the open market or in privately negotiated transactions. Except as described above, as of the filing of this Amendment No. 5, the Reporting Person does not have any definitive plans or proposals which relate to or would result in any of the following: (a) the acquisition by the Reporting Person of additional Ordinary Shares, or the disposition of Ordinary Shares that he holds; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) a change in the present board of directors or management of the Issuer, including any plan or proposal to change the number or term of directors or to fill any existing vacancies on the board; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's memorandum of association or articles of association or other actions which may impede the acquisition of control of the Issuer by any person; (h) causing the ADSs to be delisted from the Nasdaq Capital Market or any other national securities exchange on which they may be listed in the future, or to cease to be authorized to be quoted in any inter-dealer quotation system of a registered national securities association in which they may be quoted in the future; (i) causing the ADSs to become eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act; or (j) any action similar to any of those enumerated above.
Item 5.	Interest in Securities of the Issuer
(a)	The responses of the Reporting Person to Rows (11) and (13) of the cover page of this Amendment No. 5 are incorporated herein by reference. The aggregate percentage of Ordinary Shares reported as beneficially owned by the Reporting Person in this Amendment No. 5 was calculated based on 2,866,715 ordinary shares outstanding as of September 30, 2026, which information was provided by the Issuer to the Reporting Person upon his request and which reflects the Issuer's 1-for-10 reverse share split that was effective on September 4, 2026.
(b)	The responses of the Reporting Person to Rows (7) through (10) of the cover page of this Amendment No. 5 are incorporated herein by reference.
(c)	The Reporting Person has not effected any transactions in the Ordinary Shares during the 60 days preceding this Amendment No. 5.
(d)	Not applicable.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	None.
Item 7.	Material to be Filed as Exhibits.
	None.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Ami Sagy

Signature:	/s/ Ami Sagy
Name/Title:	Ami Sagy
Date:	10/08/2026